INTRODUCTION

The American Cancer Society estimated 10,400 newly diagnosed pediatric cancer cases and 1545 deaths from cancer in children in 2007. Pediatric cancer patients commonly experience adverse symptoms including nausea, physical pain, anxiety, depression, weight loss, and hair loss during treatment. As providers seek affordable palliative treatment options for pediatric patients, the use of complementary and alternative modalities (CAM) such as massage therapy (MT) is becoming popular. A study in 2003 reported that 33% of parents in a primary care setting used CAM, with MT being most commonly preferred. Research findings indicate that MT can improve circulation and immune function, dissolve soft adhesions, reduce swelling, and relieve the pain and stress associated with many illnesses. These outcomes make palliative treatment with MT a viable option for children with cancer and related blood diseases such as hemophilia.

Although MT provides a promising option for children with cancer, little data focus on this population of oncology and hematology patients. However, related research suggests that MT is an effective treatment for other pediatric populations, including premature and HIV-exposed newborns, and children with asthma, cystic fibrosis, diabetes, and rheumatoid arthritis. Documented outcomes include weight gain; reduced levels of stress hormone; decreased anxiety, stress, and depression; improved sleep; enhanced immune function; and reduced pain. Data from previous studies in various pediatric populations and settings provide supportive evidence suggesting that children with cancer and related blood diseases will receive similar benefits from MT.

Pain, a common adverse outcome associated with cancer treatment, has been defined as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage,” coupled with “the high prevalence of painful neurological conditions.” Several chemotherapeutic agents can cause peripheral neuropathy, a syndrome characterized by painful dysesthesia in the hands and feet, with associated sensory, motor, and autonomic deficits. Chronic pain can lead to disability, limited activity, and psychological problems.
Increased pain perception is also correlated with higher levels of anxiety and lower self-esteem\(^{(13)}\). The relative resistance of neuropathic pain to medication justifies the use of a modality such as MT\(^{(12,13)}\).

A review of five non-pharmacologic strategies for managing cancer pain in adults noted that MT promotes relaxation, relieves muscle spasms, reduces pain and swelling, increases blood circulation, decreases the heart rate, and inhibits transmission of noxious stimuli by stimulating large nerve fibers that reduce pain perception\(^{(14)}\). When used during chemotherapy treatment in adult populations, MT has been found to reduce anxiety, nausea, and stress; to enhance sleep; and to boost the number and function of the immune system’s natural killer cells\(^{(15,16)}\). If such improvements are replicated in future research, MT can be justified as a viable option of palliative care for pediatric cancer and blood disease patients, promoting a greater focus on healing and quality of life for these children.

The current study had three primary objectives:

- To determine the physiologic effects of MT in a pediatric oncology and hematology population
- To determine the psychological effects of MT in a pediatric oncology and hematology population
- To determine the feasibility of implementing MT as a palliative treatment option in a cancer clinic setting

The first two objectives led to the following study hypotheses:

- \(H_a1\): Children with cancer and blood diseases who receive MT will experience beneficial physiologic outcomes significantly more than will equivalent children who do not receive MT.
- \(H_a2\): Children with cancer and blood diseases who receive MT will experience beneficial psychological outcomes significantly more than will equivalent children who do not receive MT.

**METHODS**

**Participants**

Using convenience sampling, resident physicians chose 30 participants from a patient population in the pediatric hematology and oncology division at the Cancer Clinic and Shands Hospital at the University of Florida. Members of the control group (8 females, 7 males) and the treatment group (7 females, 8 males) were aged 6 months to 17 years (mean: treatment—10.7 years; control—9.3 years). There were 14 inpatients (8 control, 6 treatment) and 16 outpatients (7 control, 9 treatment). Table 1 gives descriptive statistics for the study participants. The diversity in age, disease, and inpatient or outpatient status was included to represent the diverse patient population in this clinical setting and to permit an evaluation of the feasibility of implementing massage in the clinical setting while also maximizing the external validity of the study. Participants received no compensation for their participation in the study.

**Design and Procedure**

Potential participants were identified by physicians and subsequently approached by an investigator, at which time potential participants were informed about the study process and any possible adverse effects and benefits of the study. Consent forms were given a verbal explanation. All participants were volunteers and were treated according to the ethical standards of the American Psychological Association code of conduct\(^{(17)}\).

Each participant was assigned a unique number to ensure confidentiality. Treatment and control participants were assigned to one of two schedules of four sessions each. Inpatients received daily sessions, and outpatients received weekly sessions. Sessions were conducted during regularly scheduled appointments in a treatment room or the patient’s room within the clinical setting. Treatment participants received 20 minutes of Swedish MT including effleurage (gliding stroke), petrissage (kneading), percussion (tapping with fingertips, palm, fist, or side of hand), compression (constant pressure with hand or fists), and friction (deep circular or vertical motion with fingertips). The MT was provided in the positions most comfortable for the participant, most often on the hands, feet, arms, neck, back, and shoulders. To ensure participant comfort, participants were not required to disrobe for treatment. The hospital robes worn by participants made for easy access to bare hands, feet, arms, shoulders, and backs. Covers were also provided, as in standard MT practice. The therapist (JH) is a nationally certified massage therapist, licensed in the State of Florida (where study was conducted), with 5 years of experience in the field of MT.

**Table 1** Participant Descriptive Statistics

| Group | Sex (n) | Mean age (years) | Status (n) |
|-------|--------|-----------------|------------|
|       | Male   | Female          | Inpatient  | Outpatient |
| MT    | 8      | 7               | 10.7       | 6          | 9          |
| Control | 7   | 8               | 9.3        | 8          | 7          |

MT = massage therapy.
A parent or legal guardian of the participant was present during each treatment. At each session, the massage therapist facilitated MT with the participants and thus provided a detailed demonstration for the parent or guardian, enabling parents to possibly continue implementing treatments at home; however, during the study, only the therapist provided massage to participants. Attention was given at all times to appropriate ethical procedures to ensure the safety of the participants and the continued trust and approval of the parents.

Before and after each session, the participant’s vital signs (collected by BS or clinical nursing staff), discomfort level, and Faces muscle soreness and emotional data were recorded by the research assistant (BS). The research assistant (BS) collected the general clinical progress scale after the second, third, and fourth sessions. Participants or parents (or both) completed standardized measures [the State–Trait Anxiety Inventory for Children (STAIC) and the Child Health Questionnaire–Parent (CHQ-Parent)] before the first and after the final session (collected by BS).

The data collection schedules were the same for the treatment and control groups. Control participants were seen in the same environment for the same period of time for conversation and play with the therapist. If control participants were not feeling well, the therapist sat with them quietly.

**Measures**

**Physiologic Measures**

A Faces “My muscles feel ...” soreness scale with assigned values ranging from 1 (“very sore”) to 5 (“very good”) was used to assess muscle soreness before and after each session. The pictorial Faces self-report response scales have become increasingly popular for evaluating clinical symptoms and have been found to be valid and reliable for measuring pain-related symptoms in diverse pediatric settings (18–25).

Overall discomfort level was recorded before and after each session on a scale from 0 to 4 (0 being “no discomfort,” 4 being “maximal discomfort”). This measure was collected as a verbal self-report, as is commonly done in clinical settings such as the one in which the present study was conducted.

Standard methods were used to assess the participants’ blood pressure, respiratory rate, and pulse rate before and after each session.

The Child Health Questionnaire (CHQ)–Parent (26) has two primary scales: physical health and psychological health. It has been extensively validated in evaluations of pediatric health status internationally (27–30). The physical health scale was used to assess general health physical function in study participants before and after the series of sessions.

**Psychological Measures**

The CHQ–Parent psychological health scale was used to assess general mental health in the study participants before and after the series of sessions. The STAIC (31) was used to record levels both of situational and of characteristic anxiety (minimum score: 20; maximum score: 60). The STAIC has been tested and extensively validated in diverse pediatric populations internationally (32–36). Spielberger and colleagues indicate that the State–Trait Anxiety Inventory (STAIC) and the STAIC have been used in 8000 studies and have been translated into 58 languages and dialects (35).

A Faces “I feel ...” affective scale was used to measure emotion, with a score ranging from 1 (“not good at all”) to 5 (“very good”). As with the Faces self-report pain scale, this pictorial scale has been adapted and validated for measuring emotional symptoms in diverse pediatric settings (37–40).

**General Clinical Measure**

A general clinical progress measure was collected at the end of the second, third, and fourth sessions to assess progress at each treatment or control session. This verbal self-report measure was rated on a scale from 0 to 10 (0 = no progress; 10 = maximal progress). Progress was defined as “feeling better overall, muscles and body feeling better, with less pain, and calmer with less tension.” This measure was used as a verbal self-report, commonly collected and documented in patient records—that is, clinical SOAP (subjective data, objective data, assessment, and plan) notes.

If participants were unable to respond because of age or illness, parent reports were collected to give the self-reports, consistent with common practice in clinical settings (41–49). There are constraints related to such parent-proxy reports, but Varni et al. suggest that although “pediatric patient self-report is advocated, there remains a fundamental role for parent proxy-report in pediatric clinical trials and health services research” (49).

**Data Analysis**

Statistical analyses were conducted to evaluate the mean differences between the treatment group and the control group. For measures collected before and after each session, including the Faces scales, discomfort scale, and vital signs, the differences between the groups were examined using a 2 (treatment) × 4 (time) one-way between-subjects analysis of variance (ANOVA). Additionally, 2 (treatment) × 2 (time) one-way between-subjects ANOVAs were used to compare group mean scores for the STAIC and CHQ–Parent measures taken before and after the series of sessions. Post hoc analyses using a Scheffe multiple comparisons test were conducted to identify
the source of significant differences. Because of the use of a mean composite score calculated for overall progress, an independent-samples t-test was used to determine any differences between the treatment and control groups in self-reported progress across the series of four sessions. Statistical significance was set at \( p \leq 0.05 \).

RESULTS

Physiologic Measures

Faces “My Muscles Feel ...” Scale

No significant difference was observed between treatment and control groups before treatment. However, significant mean differences on the scale of muscle soreness were found between the groups after treatment \( (F_{1,28} = 148.20, p < 0.001) \), such that members of the treatment group reported significantly less post-treatment muscle soreness than did members of the control group. Scheffe comparisons indicated that the mean values of the muscle soreness scores in the treatment group increased significantly (indicating positive change) and that no significant change occurred in the control group scores. Table 2 provides pre- and post-session means and standard deviations both for the treatment group and for the control group.

Discomfort Level

We observed no significant difference in discomfort between the two groups before treatment, but significant differences between group means were indicated after treatment \( (F_{1,238} = 50.16, p < 0.001) \),

---

**Table 2** Study Outcome Scores for the Treatment and Control Groups

| Measure and Group\(^a\) | Pre-session score [mean (SD)] | Post-session score [mean (SD)] | \(d^b\) |
|--------------------------|-----------------------------|-----------------------------|------|
| **Physiologic outcomes** |                            |                            |      |
| Faces Muscle Soreness Scale |                   |                            |      |
| MT                        | 3.06 (0.56)                | 4.53 (0.34)                | 3.03 |
| Control                   | 3.18 (0.65)                | 3.15 (0.57)                |      |
| Discomfort level          |                   |                            |      |
| MT                        | 1.90 (0.50)                | 0.13 (0.28)                | 3.38 |
| Control                   | 1.93 (0.76)                | 1.92 (0.78)                |      |
| Respiratory rate (breaths/min) |              |                            |      |
| MT                        | 21.20 (1.82)               | 17.93 (1.87)               | 1.68 |
| Control                   | 21.80 (3.08)               | 21.6 (2.50)                |      |
| Pulse (beats/min)         |                   |                            |      |
| MT                        | 96.80 (17.30)              | 92.58 (17.73)              | 0.14 |
| Control                   | 95.02 (24.07)              | 95.62 (26.71)              |      |
| Systolic blood pressure (mmHg) |        |                            |      |
| MT                        | 112.75 (12.21)             | 116.20 (16.32)             | 0.07 |
| Control                   | 114.55 (13.97)             | 117.25 (14.64)             |      |
| Diastolic blood pressure (mmHg) |               |                            |      |
| MT                        | 63.60 (10.75)              | 64.07 (10.24)              | -0.04 |
| Control                   | 62.63 (11.94)              | 63.57 (12.80)              |      |
| CHQ–Parent, physical health scale |       |                            |      |
| MT                        | 25.01 (9.55)               | 19.08 (11.99)              | 0.51 |
| Control                   | 25.01 (11.41)              | 24.91 (10.98)              |      |
| Psychological outcomes    |                   |                            |      |
| CHQ–Parent, psychological health scale |     |                            |      |
| MT                        | 43.80 (8.35)               | 46.51 (9.10)               | 0.30 |
| Control                   | 42.37 (3.76)               | 43.98 (7.75)               |      |
| State Anxiety Inventory for Children |       |                            |      |
| MT                        | 33.87 (6.82)               | 23.00 (2.83)               | 2.55 |
| Control                   | 35.93 (8.08)               | 37.73 (8.73)               |      |
| Trait Anxiety Inventory for Children |       |                            |      |
| MT                        | 32.87 (5.42)               | 27.73 (2.94)               | 1.98 |
| Control                   | 34.07 (5.12)               | 37.33 (6.77)               |      |
| Faces Emotion Scale       |                   |                            |      |
| MT                        | 3.33 (0.49)                | 4.82 (0.42)                | 3.33 |
| Control                   | 3.35 (0.50)                | 3.27 (0.51)                |      |

\(^{a}\) \( n = 15 \) for each group.

\(^{b}\) Values are between-groups standardized mean effect sizes; a positive value indicates a better outcome for the MT group.

SD = standard deviation; MT = massage therapy; CHQ = Child Health Questionnaire.
such that the treatment group reported significantly less discomfort than did the control group. Scheffe comparisons showed that the mean values of the treated group’s discomfort level scores declined significantly, but that no significant change occurred in the control group scores. Table 2 provides pre- and post-session means and standard deviations both for the treatment group and for the control group.

**Vital Signs**

We observed no significant difference between the groups in pulse rate ($F_{1,58} = 0.049$, $p < 0.825$) or in systolic ($F_{1,238} = 0.593$, $p < 0.442$) and diastolic blood pressure ($F_{1,238} = 0.246$, $p < 0.620$), before or after treatments. However, MT affected respiratory rate ($F_{1,237} = 22.47$, $p < 0.000$), such that, post-treatment, the rate declined significantly in the treatment group as compared with the control group. Scheffe comparisons indicated that the mean values of the treated group’s respiratory rate declined significantly; no significant change was observed in the scores for the control group. Table 2 provides pre- and post-session means and standard deviations both for the treatment group and for the control group.

**CHO–Parent, Physical Scale**

On the CHQ–Parent questionnaire, we found no significant differences between the treatment and control groups for physical health, before or after treatments ($F_{1,58} = 1.05$, $p = 0.310$). Table 2 provides pre- and post-session means and standard deviations both for the treatment group and for the control group.

**Psychological Measures**

**CHQ–Parent, Psychological Scale**

On the CHQ–Parent questionnaire, we found no significant differences between the treatment and control groups for psychological health, before or after treatments ($F_{1,58} = 1.06$, $p = 0.308$). Table 2 provides pre- and post-session means and standard deviations both for the treatment group and for the control group.

**State Anxiety Inventory for Children**

We observed no group difference in the State Anxiety Inventory for Children before treatment. Post-treatment levels of state anxiety were lower in the treatment group than in the control group ($F_{1,58} = 16.79$, $p < 0.000$). Scheffe comparisons indicated that the mean values of the state anxiety scores in the treatment group declined significantly; no significant change occurred in the scores for the control group. Table 2 provides pre- and post-session means and standard deviations both for the treatment group and for the control group.

**Trait Anxiety Inventory for Children**

We observed no significant difference between the two groups in the Trait Anxiety Inventory for Children before treatments, but a significant treatment effect was evident for the treatment group as compared with the control group after the series of sessions ($F_{1,58} = 13.95$, $p < 0.000$), such that the treatment group reported significantly decreased trait anxiety. The control group reports showed no significant change. Scheffe comparisons indicated that the mean values of the trait anxiety scores declined significantly in the treatment group; no significant change was observed in the scores for the control group. Table 2 provides pre- and post-session means and standard deviations both for the treatment group and for the control group.

**Faces Emotion “I Feel ...” Scale**

The treatment and control groups showed no significant differences in their Faces “I Feel ...” scores before treatment. However, post-treatment, the treatment and control group means showed significant differences ($F_{1,238} = 42.39$, $p < 0.001$), such that the treatment group reported feeling significantly better, and the control group reported no significant change. Scheffe comparisons indicated that the mean values of the emotion scores in the treatment group improved significantly. We observed no significant change in the scores for the control group. Table 2 provides pre- and post-session means and standard deviations both for the treatment group and for the control group.

**General Clinical Progress Scale**

We found significant differences in the mean progress scores between the treatment and control groups ($t_{28} = 25.55$, $p < 0.001$). The treatment group reported significant progress after the treatment series; the control group reported no change. Mean value [standard deviation (SD)] for the control group was 0.49 (0.87); for the treatment group, it was 8.62 (0.87).

**DISCUSSION**

Research into MT in the area of pediatric oncology and hematology is limited. The present study was conducted to examine the physiologic and psychological effects of MT on children with cancer and blood diseases. Our findings indicate a general improvement in physical and psychological well-being that supports both hypotheses posited in this study—findings that are largely consistent with those reported in related research (4–7,14).

As seen in other cancer populations, the findings in this study are consistent with the positive rehabilitative effect of MT (5,6,14). Physiologic measures suggest that MT reduced muscle soreness, discomfort, and respiratory rate. Psychological measures indicate that MT reduced state and trait anxiety and positively influenced overall emotional well-being, and they support prior findings that indicate that lasting psychological effects result from MT (3,5–8). Additionally, the general clinical progress found in the treatment group suggests that MT can provide a general improvement in quality of life.
In relating measure outcomes, participants who received MT experienced a significant reduction in muscle soreness and discomfort that corresponded with slowed respiration, improvement in emotional state, and overall progress. The combination of muscle relaxation and decreased anxiety suggest that MT can induce a general sense of relaxation for recipients. Considered together, these psychophysiologic effects indicate that MT could also promote optimal immune system functioning, although the current study does not examine that effect directly. Current findings also indicate that MT can be effectively implemented within an oncology setting and can provide significant palliative benefits to pediatric recipients across a diverse age range and disease population. The results indicate that clinicians, parents, and other caregivers should consider MT a viable palliative intervention for symptom relief in children with cancer and blood disease.

It should be noted that, because parents or guardians were present for each child’s treatments (which could serve as demonstrations of how MT can be provided), it is possible they may have spontaneously provided additional MT to outpatient participants in the home setting. Data concerning this possibility were not collected in the current study. We recommend that future pediatric studies collect such data from parents or guardians to account for potential confounding effects. Further, bias may have occurred in self-reports from the participants or their parents (or both) because of expectancy or social desirability effects. Finally, this pilot study did not collect data on symptoms such as nausea, headaches, and pain around access portals, although many participants reported a decrease in such symptoms. These validity threats should be addressed in subsequent studies.

Our pilot study needs to be replicated in a larger sample of patients that would allow for subgroup analysis by age, diagnosis, stage and severity of disease, and inpatient or outpatient status. A larger study might also examine the effects of MT on a diverse range of symptomology. Further, a larger study would also allow for more robust complex multivariate statistical analyses and, potentially, broader generalization of the findings.

CONCLUSIONS

The findings of this pilot study suggest that MT can be effectively implemented for pediatric oncology and hematology patients within the clinical setting to reduce adverse physical and psychological symptoms associated with cancer treatment and cancer pain. The successful recruitment and implementation in inpatient and outpatient recipients alike suggest that positive outcomes associated with MT can be achieved both for oncology and for hematology pathologies, for girls and for boys, in a wide range of age groups, in diverse clinical environments. Although cancer clinics and oncology/hematology wards are hectic clinical settings that must provide necessarily invasive clinical care such as chemotherapy, which clearly comprises the immune system, our data suggest that the addition of MT as a palliative treatment can increase quality of life and the health of pediatric oncology and hematology patients.

CONFLICT OF INTEREST NOTIFICATION

Dr. Haun and co-authors conducted this research at the University of Florida, College of Psychology, and the Cancer Center at Shands Hospital. Research was conducted in cooperation with the Shands Hospital and the University of Florida. Dr. Haun is now at the University of Arizona College of Medicine. This publication was made possible in part by grant T32 AT001287 from the National Center for Complementary and Alternative Medicine (NCCAM). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM, the National Institutes of Health, Shands Hospital, or the University of Florida. The authors declare that there are no conflicts of interest.

COPYRIGHT

Published under the CreativeCommons Attribution-NonCommercial-NoDerivs 3.0 License.

REFERENCES

1. The American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Loman DG. The use of complementary and alternative health care practices among children. J Pediatr Health Care. 2003; 17(2):58–63.
3. Field T. Massage therapy for infants and children. J Dev Behav Pediatr. 1995; 16(2):105–111.
4. Yates J. A Physician’s Guide to Therapeutic Massage: Its Physiological Effects and Their Application to Treatment. Canada: Massage Therapists’ Association of British Columbia; 1990.
5. Beider S, Moyer CA. Randomized controlled trials of pediatric massage: a review. Evid Based Complement Alternat Med. 2007; 4(1):23–34.
6. Cassileth BR, Vickers AJ. Massage therapy for symptom control: outcome study at a major cancer center. J Pain Symptom Manage. 2004; 28(3):244–249.
7. Field T, Hernandez-Reif M, Seligman S, Krasnegor J, Sunshine W, Rivas-Chacon R, et al. Juvenile rheumatoid arthritis: benefits from massage therapy. J Pediatr Psychol. 1997; 22(5):607–17.
8. Field T, Henteleff T, Hernandez-Reif M, Martinez E, Mavunda K, Kuhn C, et al. Children with asthma have improved pulmonary function after massage therapy. J Pediatr. 1998; 132(5):854–858.
9. Field T, Hernandez-Reif M, LaGreca A, Shaw K, Schanberg S, Kuhn C. Lifestyle and behavior: massage therapy lowers blood
glucose levels in children with diabetes mellitus. *Diabetes Spectrum.* 1997; 10(4): 237–9.

10. Hernandez-Reif M, Field T, Krasnegor J, Martinez E, Schwartzman M, Mavunda K. Children with cystic fibrosis benefit from massage therapy. *J Pediatr Psychol.* 1999; 24(2): 175–181.

11. Scafidi F, Field T, Schanberg S, Bauer C, Tucci K, Roberts J, et al. Massage stimulates growth in preterm infants: a replication. *Infant Behav Dev.* 1990; 13(2): 167–188.

12. Martin LA, Hagen NA. Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. *J Pain Symptom Manage.* 1997; 14(2): 99–117.

13. Varni JW, Rapoff MA, Waldron SA, Gragg RA, Bernstein BH, Lindsey CB. Chronic pain and emotional distress in children and adolescents. *J Dev Behav Pediatr.* 1996; 17(3): 154–161.

14. Sellick SM, Zaza C. Critical review of 5 nonpharmacologic strategies for managing cancer pain. *Cancer Prev Control.* 1998; 2(1): 7–14.

15. Ironson G, Field T, Scafidi F, Hashimoto M, Kumar M, Kumar A, et al. Massage therapy is associated with enhancement of the immune system’s cytotoxic capacity. *Int J Neurosci.* 1996; 84(1-4): 205–217.

16. Lerner M. *Choices in Healing: Integrating the Best of Conventional and Complementary Approaches to Cancer.* Cambridge, MA: MIT Press; 1994.

17. American Psychological Association. Ethical principles of psychologists and code of conduct. *Am Psychol.* 1991; 46(2): 1597–1611.

18. Wong DL, Baker CM. Pain in children: comparison of assessment scales. *Pediatr Nurs.* 1988; 14(1):9–17.

19. McGrath PA, Seifert CE, Speechley KN, Booth JC, Stitt L, Gibson MC. A new analogue scale for assessing children’s pain: an initial validation study. *Pain.* 1996; 64(3): 435–443.

20. Chambers CT, Chiesbrecht K, Craig KD, Bennett SM, Huntsman E. A comparison of Faces scales for the measurement of pediatric pain: children’s and parents’ ratings. *Pain.* 1999; 83(1): 25–35.

21. Chambers CT, Hardial J, Craig KD, Court C, Montgomery C. Faces scales for the measurement of postoperative pain intensity in children following minor surgery. *Clin J Pain.* 2005; 21(3): 277–285.

22. Perrott DA, Goodenough B, Champion GD. Children’s ratings of the intensity and unpleasantness of post-operative pain using facial expression scales. *Eur J Pain.* 2004; 8(2): 119–127.

23. Miró J, Huguet A. Evaluation of reliability, validity, and preference for a Pediatric Pain Intensity Scale: the Catalan version of the Faces Pain Scale–Revised. *Pain.* 2004; 111(1-2): 59–64.

24. Bieri D, Reeve RA, Champion GD, Addicoat L, Ziegler JB. The Faces Pain Scale for the self-assessment of the severity of pain experienced by children: development, initial validation, and preliminary investigation for ratio scale properties. *Pain.* 1990; 41(2): 139–150.

25. Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B. The Faces Pain Scale–Revised: toward a common metric in pediatric pain measurement. *Pain.* 2001; 93(2): 173–183.

26. Landgraf JM, Abetz L, Ware JE. *The CHQ User’s Manual.* Boston, MA: The Health Institute, New England Medical Center; 1996.

27. Raat H, Botterweck A, Landgraf J, Hoogeveen W, Essink-Bot M. Reliability and validity of the short form of the Child Health Questionnaire for Parents (CHQ-PF28) in large random school based and general population samples. *J Epidemiol Community Health.* 2005; 59(1): 75–82.

28. McCarthy ML, Silberstein CE, Atkins EA, Harryman SE, Sponseller PD, Hadley-Miller NA. Comparing reliability and validity of pediatric instruments for measuring health and well-being of children with spastic cerebral palsy. *Dev Med Child Neurolog.* 2002; 44(7): 468–476.

29. Waters E, Salmon L, Wake M. The parent-form Child Health Questionnaire in Australia: comparison of reliability, validity, structure, and norms. *J Pediatr Psychol.* 2000; 25(6): 381–391.

30. Edmunds S, Garratt A, Haines L, Blair M. Child Health Assessment at School Entry (CHASE) project: evaluation in 10 London primary schools. *Child Care Health Dev.* 2005; 31(2): 143–154.

31. Spielberger CD, Edwards CD, Lushene RE, Montuori J, Platzer D. STAIC Preliminary Manual. Palo Alto, CA: Consulting Psychologists Press; 1971.

32. Edwards D. Effects of midterm integration on state and trait anxiety in black and white elementary school children. *Am J Community Psychol.* 1979; 7(1): 57–70.

33. Hishinuma ES, Miyamoto RH, Nishimura ST, Nahulu LB, Andrade NN, Makini GK Jr, et al. Psychometric properties of the State–Trait Anxiety Inventory for Asian/Pacific-Islander adolescents. *Assessment.* 2000; 7(1): 17–36.

34. Turgeon L, Chartrand E. Psychometric properties of the French Canadian version of the State–Trait Anxiety Inventory for children. *Educ Psychol Measure.* 2003; 63(1): 174–185.

35. Spielberger CD, Sydeman SJ, Owen AE, Marsh B. Measuring anxiety and anger with the State–Trait Anxiety Inventory (STAI) and the State–Trait Anger Expression Inventory (STAXI). In: Maruish ME, ed. *The Use of Psychological Testing for Treatment Planning and Outcomes Assessment.* 2nd ed. Mahwah, NJ: Lawrence Erlbaum Associates; 1999: 1007–1008.

36. Spielberger CD, Edwards CD, Montuori J, Lushene R. State–Trait Anxiety Inventory for Children. Mind Garden website. http://www.mindgarden.com/products/staisch.htm. Published n.d. Accessed October 30, 2008.

37. McKinley S, Coote K, Stein-Parbury J. Development and testing of a Faces scale for the assessment of anxiety in critically ill patients. *J Adv Nurs.* 2003; 41(1): 73–79.

38. Gustad LT, Chaboyer W, Wallis M. Performance of the Faces Anxiety Scale in patients transferred from the ICU. *Intensive Crit Care Nurs.* 2005; 21(6): 355–360.

39. McKinley S, Stein-Parbury J, Chehelnabi A, Lovas J. Assessment of anxiety in intensive care patients by using the Faces Anxiety Scale. *Am J Crit Care.* 2004; 13(2): 146–152.

40. McKinley S, Madronico C. Validity of the Faces Anxiety Scale for the assessment of state anxiety in intensive care patients not receiving mechanical ventilation. *J Psychosom Res.* 2008; 64(5): 503–507.

41. Varni JW, Katz ER, Colegrove R, Dolgin M. Adjustment of children with newly diagnosed cancer: cross-informant variance. *J Psychosom Oncol.* 1995; 13(4): 23–38.
42. Varni JW, Katz ER, Seid M, Quiggins DJL, Friedman-Bender A, Castro CM. The Pediatric Cancer Quality of Life Inventory (PCQL): I. Instrument development, descriptive statistics, and cross-informant variance. *J Behav Med.* 1998; 21(2): 179–204.

43. Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the Pediatric Quality of Life Inventory. *Med Care.* 1999; 37(2): 126–139.

44. Levi RB, Drotar D. Health-related quality of life in childhood cancer: discrepancy in parent–child reports. *Int J Cancer Suppl.* 1999; 12: 58–64.

45. Felder-Puig R, diGallo A, Waldenmair M, Norden P, Winter A, Gadner H, et al. Health-related quality of life of pediatric patients receiving allogeneic stem cell or bone marrow transplantation: results of a longitudinal, multi-center study. *Bone Marrow Transplant.* 2006; 38(2): 119–126.

46. Vance YH, Morse RC, Jenney ME, Eiser C. Issues in measuring quality of life in childhood cancer: measures, proxies, and parental mental health. *J Child Psychol Psychiatry.* 2001; 42(5): 661–667.

47. Chang P, Yeh C. Agreement between child self-report and parent proxy-report to evaluate quality of life in children with cancer. *Psychooncology.* 2005; 14(2): 125–134.

48. Yeh CH, Chang CW, Chang PC. Evaluating quality of life in children with cancer using children’s self-reports and parent-proxy reports. *Nurs Res.* 2005; 54(5): 354–362.

49. Varni JW, Limbers CA, Burwinkle TM. Parent proxy-report of their children’s health-related quality of life: an analysis of 13,878 parents’ reliability and validity across age subgroups using the PedsQL 4.0 Generic Core Scales. *Health Qual Life Outcomes.* 2007; 5: 2.

**Corresponding author:** Jolie N. Haun, 3750 E. Via Palomita #30202, Tucson, Arizona 85718 USA. 
**E-mail:** joliehaun@gmail.com